Bruce Shiramizu to Burkitt Lymphoma
This is a "connection" page, showing publications Bruce Shiramizu has written about Burkitt Lymphoma.
Connection Strength
1.260
-
Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. Br J Haematol. 2015 Aug; 170(3):367-71.
Score: 0.513
-
Cabalo E, Wilkinson R, Lu NT, Shimizu S, Melish M, McClain KL, Jenson HB, Shiramizu B. Molecular analysis and pathology of a second pediatric HIV-associated Burkitt lymphoma. Pediatr Pathol Mol Med. 2002 Nov-Dec; 21(6):525-30.
Score: 0.217
-
Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014 Nov; 167(3):394-401.
Score: 0.122
-
Shiramizu B, Barriga F, Neequaye J, Jafri A, Dalla-Favera R, Neri A, Guttierez M, Levine P, Magrath I. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood. 1991 Apr 01; 77(7):1516-26.
Score: 0.097
-
Shiramizu B, Magrath I. Localization of breakpoints by polymerase chain reactions in Burkitt's lymphoma with 8;14 translocations. Blood. 1990 May 01; 75(9):1848-52.
Score: 0.091
-
Magrath I, Barriga F, McManaway M, Shiramizu B. The molecular analysis of chromosomal translocations as a diagnostic, epidemiological and potentially prognostic tool in lymphoid neoplasia. J Virol Methods. 1988 Sep; 21(1-4):275-89.
Score: 0.081
-
Sabesan V, Cairo MS, Lones MA, Perkins SL, Morris E, Sposto R, Van De Ven C, Shiramizu B. Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers. J Pediatr Hematol Oncol. 2003 Feb; 25(2):109-13.
Score: 0.055
-
Frazer JK, Li KJ, Galardy PJ, Perkins SL, Auperin A, Anderson JR, Pinkerton R, Buxton A, Gross TG, Michon J, Leverger G, Weinstein HJ, Harrison L, Shiramizu B, Barth MJ, Goldman SC, Patte C, Cairo MS. Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol. 2019 04; 185(2):374-377.
Score: 0.040
-
McManaway ME, Neckers LM, Loke SL, al-Nasser AA, Redner RL, Shiramizu BT, Goldschmidts WL, Huber BE, Bhatia K, Magrath IT. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet. 1990 Apr 07; 335(8693):808-11.
Score: 0.023
-
Barriga F, Kiwanuka J, Alvarez-Mon M, Shiramizu B, Huber B, Levine P, Magrath I. Significance of chromosome 8 breakpoint location in Burkitt's lymphoma: correlation with geographical origin and association with Epstein-Barr virus. Curr Top Microbiol Immunol. 1988; 141:128-37.
Score: 0.019